Genomate Health
Genomate Health builds a proprietary computational reasoning platform that ranks targeted cancer therapies for each patient's full molecular profile, serving U.S. oncologists, cancer patients via telehealth, biopharma partners, and European oncology providers through its Oncompass Medicine subsidiary.
- Company typePrivate
- Founded2022
- HeadquartersCambridge, United States
- Headcount11–50
- GTM typeB2B and B2C
- OfferingSoftware
What Genomate Health does
Genomate Health is a Cambridge, Massachusetts-based digital health company founded in 2022 that develops Genomate®, a proprietary computational reasoning platform for precision oncology. The platform ingests Next Generation Sequencing (NGS) reports and, rather than matching one drug to one biomarker as is standard, analyzes the totality of a patient's genetic alterations simultaneously against an evidence database of thousands of sources and over six million potential mutations across 600+ cancer genes to produce a ranked, personalized list of targeted therapies. Clinical validation published in Nature NPJ Precision Oncology, ASCO, AACR, and ESMO reports a 4X higher positive response rate in the SHIVA01 trial, 2.6X longer overall survival and 3X longer progression-free survival in real-world lung cancer, and 72% actionable pairing in pediatric oncology.
The company monetizes through three distinct streams: a Genomate Report clinical decision support subscription for oncologists (delivered in 2–3 days), a physician-led AI-powered Second Opinion Service sold direct-to-consumer via telehealth in 11 U.S. states and eligible for HSA/FSA reimbursement, and biopharma professional services for drug target identification and disease pathway analysis. Distribution combines U.S. enterprise sales to oncologists, payers, cancer centers, and labs with exclusive distributor partnerships in Vietnam (Digosys/Thabis) and India (Intelligene Healthcare), plus a European operational base established through the January 2026 acquisition of Hungary-based Oncompass Medicine (founded 2003). The platform is HIPAA-secure, ISO 13485 certified, and ISO/IEC 27001:2022 certified (BSI, April 2025).
The company has raised approximately $4.25 million in disclosed venture funding across 2024 and 2025 rounds, plus an earlier Oktogon Ventures round, and operates with 11–50 employees. In May 2025 it appointed Nabil Hafez as CEO to lead commercial expansion, with founder Dr. Istvan Petak continuing as Chief Scientific Officer; Dr. Petak simultaneously serves as Managing Director of the Oncompass Medicine subsidiary, signaling an integrated transatlantic precision oncology group that sells direct to U.S. oncologists and patients, distributes through partners in Asia, and operates clinical services in Europe.
Genomate Health firmographics
Firmographics- Name
- Genomate Health
- Legal name
- Genomate Health Inc.
- Website
- https://genomate.health
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Genomate Health builds a proprietary computational reasoning platform that ranks targeted cancer therapies for each patient's full molecular profile, serving U.S. oncologists, cancer patients via telehealth, biopharma partners, and European oncology providers through its Oncompass Medicine subsidiary.
- Ownership category
- akta.pro rank
Genomate Health industry classification
Industry- Product category
- Precision Oncology Clinical Decision Support
- NAICS
- Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design Services (541512)
- SIC
- Services-Medical Laboratories (8071), Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Oncology Pathways & Precision Medicine Decision Support (HLACAGAH)
- akta.pro secondary industries
- Molecular Tumor Boards & Clinical Interpretation Services (HLAAANAD), Genomic Profiling & Sequencing-Based Precision Medicine (HLAAANAA), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)
Keywords
Where Genomate Health is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
Genomate Health business model
Business model- GTM type
- B2B and B2C
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Second Opinion Service: Physician-led, AI-powered second opinion service for cancer patients, available via telehealth in U.S. states. Multidisciplinary team of molecular genetics counselors and board-certified oncologists reviews patient findings. Patients receive written reports covering treatment options, clinical reasoning, and supporting literature.
- Genomate Report for Oncologists: Clinical decision support reports for oncologists analyzing patient NGS data to generate actionable treatment recommendations. Oncologists upload existing NGS reports and receive prioritized therapy recommendations within 2-3 days.
- Biopharma partnerships: Partnership services with biopharma companies for drug target identification, novel therapeutic target discovery, and understanding disease pathways through analysis of relationships between drugs, targets, genes, and diseases.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Second Opinion Service for patients |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels6 records
Genomate Health product offering
Product offeringCore offering
Genomate Health develops and sells the Genomate® computational reasoning platform, an AI-powered clinical decision support system for precision oncology that analyzes patients' Next Generation Sequencing (NGS) reports to rank targeted cancer therapies based on the totality of a tumor's genetic alterations. The company also offers a physician-led Second Opinion Service via telehealth for U.S. patients and Biopharma partnership services for drug target identification.
Product overview
Genomate Health offers Genomate®, the world's first AI-powered clinical decision support system for precision oncology that uses computational reasoning to match targeted therapies to the totality of available molecular information for each patient. The core Genomate® platform analyzes Next Generation Sequencing (NGS) reports and genetic alterations to rank optimal treatment options. The company provides a Second Opinion Service that combines AI-powered computational reasoning with physician-led expert review for patients and oncologists. Additional offerings include the Precision Care Pledge (free reports for licensed physicians) and the recently acquired European brand Oncompass Medicine (founded 2003, Budapest). Solutions are targeted at oncologists, biopharma companies, healthcare partners (payers, cancer centers, labs), and patients.
Differentiator
Problem solved
Functional benefit
Brands
- Oncompass Medicine, a Genomate Health company: Retained brand following acquisition; provides precision oncology services, companion diagnostics, and molecular tumor profiling in Europe.
Products and services
- Genomate® Computational Reasoning Platform The first clinically validated universal computational reasoning platform that predicts response to multiple targeted therapies by analyzing each patient's unique combinations of genetic alterations and biomarkers. Oncologists upload existing NGS reports and receive ranked, actionable therapy recommendations within 2-3 days. Analyzes over 6 million potential mutations across 600+ cancer genes simultaneously, working with existing sequencing providers without requiring lab changes.
- Second Opinion Service Physician-led, AI-powered second opinion service that combines Genomate's computational reasoning analysis with multidisciplinary expert review. Available via telehealth for U.S. patients in 11 states (Texas, Georgia, Missouri, California, Florida, Arizona, Mississippi, Kentucky, Illinois, Oklahoma, Washington), with HSA/FSA reimbursement eligibility. Includes written reports covering treatment options, clinical reasoning, and supporting literature.
- Oncompass Medicine Precision Oncology Services Personalized oncology services including companion diagnostics, molecular diagnostics, advanced bioinformatics, and molecular tumor profiling. Pioneered companion diagnostic tests for precision oncology in 2003 and was among the first to implement NGS-based tumor profiling in routine clinical care in 2008. Now operates as Genomate Health's diagnostic service provider in Europe, headquartered in Budapest, Hungary.
Quantifiable outcome
- 4X higher positive response rate for patients receiving Genomate-recommended targeted therapy vs single biomarker approach in SHIVA01 clinical trial
- +5 more outcomes
Companies that use Genomate Health
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles4 records
Genomate Health technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature4 records
Genomate Health partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Oncompass MedicinecoreAcquisition of Hungary-based Oncompass Medicine, a pioneer in personalized oncology founded in Budapest in 2003. Oncompass pioneered companion diagnostic tests for precision oncology in 2003 and was among first to implement NGS-based tumor profiling in routine clinical care in 2008. The acquisition establishes Genomate Health's European operational base and creates unified precision oncology company combining computational reasoning technology with clinical expertise. Dr. Istvan Petak serves as Managing Director of Oncompass Medicine. Brand continues as 'Oncompass Medicine, a Genomate Health company'.
Scale indicators14 records
Recent moves6 records
Expansion highlights6 records
Genomate Health competitors and assessment
Company assessmentDirect peers
- CureMatch: CureMatch offers an AI-driven preciSION oncology decision support tool (MatchMaker) that ranks combination and monotherapy options based on a patient's molecular profile; it directly mirrors Genomate's therapy-ranking functionality and serves the same oncologist and patient segments.
- Syapse: Syapse operates a precision oncology platform that integrates real-world clinical and molecular data to support treatment decisions and payer coverage; it is comparable to Genomate in combining molecular analysis with payer-ready evidence generation for oncology decision support.
- MolecularMatch: MolecularMatch is a clinical decision support platform that matches patient molecular profiles to targeted therapies, clinical trials, and approved drugs; it is the closest direct peer to Genomate's computational reasoning engine, with a similar therapy-ranking value proposition for oncologists.
Broad incumbents
- Tempus AI: Tempus is a large, well-capitalized AI-powered precision medicine company offering NGS profiling, clinical decision support, and biopharma data services across oncology; it competes with Genomate in AI-driven therapy ranking and biopharma target identification, though its portfolio is much broader (multi-omics, clinical trial matching, imaging).
- Flatiron Health: Flatiron Health (a Roche subsidiary) provides real-world oncology data, electronic medical record solutions, and clinical decision support for cancer care; it is comparable to Genomate in oncology-specific data infrastructure and biopharma evidence generation, though with a much broader footprint.
- Caris Life Sciences: Caris provides comprehensive molecular profiling (DNA, RNA, protein) and AI-driven precision oncology insights including therapy recommendations and clinical trial matching; it overlaps with Genomate's NGS-based therapy ranking and serves the same oncologist and biopharma customer segments.
- Foundation Medicine: Foundation Medicine (a Roche subsidiary) is a leading provider of comprehensive genomic profiling assays (FoundationOne CDx) used to inform targeted therapy selection in oncology; it sits upstream of Genomate because Genomate ingests NGS reports, but both compete for influence over oncologists' therapy decisions.
Emerging players
- PathAI: PathAI provides AI-powered pathology diagnostics with a focus on oncology biomarker detection from tissue images; it is an adjacent emerging player because it operates in AI-driven cancer diagnostics, although its modality (digital pathology) differs from Genomate's NGS-based computational reasoning.
- Owkin: Owkin applies AI to biomedical research and precision oncology, with a focus on federated learning, biopharma partnerships, and patient stratification; it is an emerging player in AI-driven oncology decision support that overlaps with Genomate's predictive analytics and biopharma services.
- Onc.AI: Onc.AI uses AI to analyze real-world oncology data and inform clinical and commercial decisions for cancer care; it overlaps with Genomate's biopharma data partnership and therapy selection support offerings, though with more emphasis on population-level analytics.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Genomate Health social profiles
Digital presenceGenomate Health compliance and trust
Trust signalCompliance6 records
Genomate Health financial estimates
Financial estimateRevenue estimate
Valuation estimate
Genomate Health leadership team
Management profileNumber of profiles
Profiles12 records
Genomate Health subsidiaries and ownership
Company hierarchySubsidiaries1 record
Genomate Health funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Genomate Health M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Genomate Health
What does Genomate Health do?
Genomate Health develops and sells the Genomate® computational reasoning platform, an AI-powered clinical decision support system for precision oncology that analyzes patients' Next Generation Sequencing (NGS) reports to rank targeted cancer therapies based on the totality of a tumor's genetic alterations. The company also offers a physician-led Second Opinion Service via telehealth for U.S. patients and Biopharma partnership services for drug target identification.
Is Genomate Health a public or private company?
Genomate Health is a private company. It is classified as venture growth investor backed and is currently operating.
When was Genomate Health founded?
Genomate Health was founded in 2022. It employs 11 to 50 people.
Where is Genomate Health based?
Genomate Health is headquartered in Cambridge, United States, in the North America region.
How does Genomate Health make money?
Three revenue lines are on record. Second Opinion Service is the primary driver. The others are genomate Report for Oncologists and biopharma partnerships.
Who are Genomate Health's main competitors?
Direct peers on record are CureMatch, Syapse and MolecularMatch. Broad incumbents are Tempus AI, Flatiron Health, Caris Life Sciences and Foundation Medicine. Emerging players are PathAI, Owkin and Onc.AI.
Does Genomate Health have an API?
No public API is recorded for Genomate Health.
What industry is Genomate Health in?
Genomate Health's product category is Precision Oncology Clinical Decision Support. Its primary akta.pro industry code is HLACAGAH, Oncology Pathways & Precision Medicine Decision Support, with a secondary code of HLAAANAD, Molecular Tumor Boards & Clinical Interpretation Services. Its NAICS code is 621511 and its SIC code is 8071.